Published in CMAJ on June 05, 2017
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med (1999) 29.32
Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med (2004) 11.44
Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension (2011) 4.61
Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol (2005) 4.20
Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens (2005) 4.19
A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol (2006) 3.74
Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab (2004) 2.56
Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension (2002) 2.46
Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension (2013) 2.25
The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab (2016) 1.89
Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A (2003) 1.74
High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. J Hypertens (2003) 1.70
Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res (2004) 1.68
A clinical prediction score to diagnose unilateral primary aldosteronism. J Clin Endocrinol Metab (2012) 1.64
Prevalence of primary aldosteronism among unselected hypertensive patients: a prospective study based on the use of an aldosterone/renin ratio above 25 as a screening test. Hypertens Res (2007) 1.61
Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med (2008) 1.53
Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Can J Cardiol (2016) 1.52
Epidemiology of Hypertension in Canada: An Update. Can J Cardiol (2015) 1.50
High-probability features of primary aldosteronism may obviate the need for confirmatory testing without increasing false-positive diagnoses. J Clin Hypertens (Greenwich) (2014) 1.45
Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int (2005) 1.40
Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab (2000) 1.36
Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens (2003) 1.35
Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol (2010) 1.35
Long-term renal outcomes in patients with primary aldosteronism. JAMA (2006) 1.35
Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis (2001) 1.31
Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin Endocrinol Metab (2009) 1.30
Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab (2013) 1.15
Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality. J Am Soc Hypertens (2014) 1.13
Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension. Am J Hypertens (2005) 1.08
Aldosterone promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid receptors. Arterioscler Thromb Vasc Biol (2013) 1.04
The role of aldosteronism in causing obesity-related cardiovascular risk. Cardiol Clin (2010) 1.04
Role for germline mutations and a rare coding single nucleotide polymorphism within the KCNJ5 potassium channel in a large cohort of sporadic cases of primary aldosteronism. Hypertension (2014) 1.03
High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens (2000) 1.01
Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension. Hypertens Res (1997) 0.98
Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br J Clin Pharmacol (1999) 0.95
A Meta-Analysis of Somatic KCNJ5 K(+) Channel Mutations In 1636 Patients With an Aldosterone-Producing Adenoma. J Clin Endocrinol Metab (2015) 0.92
Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases. J Clin Endocrinol Metab (2013) 0.91
Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin. Br Med J (1972) 0.90
Confirmatory testing in primary aldosteronism. J Clin Endocrinol Metab (2012) 0.86
Chronic kidney disease score for predicting postoperative masked renal insufficiency in patients with primary aldosteronism. Clin Endocrinol (Oxf) (2014) 0.85
Role of mineralocorticoid receptor antagonists in cardiovascular disease. Circ Res (2015) 0.85
Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone? Am J Hypertens (2005) 0.85
Prevalence of adrenal and extra-adrenal Conn syndrome in hypertensive patients. Arch Intern Med (1996) 0.85
Study Heterogeneity and Estimation of Prevalence of Primary Aldosteronism: A Systematic Review and Meta-Regression Analysis. J Clin Endocrinol Metab (2016) 0.84
Positive relationship of sleep apnea to hyperaldosteronism in an ethnically diverse population. J Hypertens (2011) 0.83
Aberrant hormone receptors in primary aldosteronism. Horm Metab Res (2010) 0.83
Medical or surgical therapy for primary aldosteronism: post-treatment follow-up as a surrogate measure of comparative outcomes. Ann Surg Oncol (2013) 0.82
Dietary Sodium Restriction Increases the Risk of Misinterpreting Mild Cases of Primary Aldosteronism. J Clin Endocrinol Metab (2016) 0.82
Laboratory challenges in primary aldosteronism screening and diagnosis. Clin Biochem (2015) 0.81
Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn's Registry. Eur J Endocrinol (2015) 0.81
Aldosterone Impairs Vascular Smooth Muscle Function: From Clinical to Bench Research. J Clin Endocrinol Metab (2015) 0.81
Primary aldosteronism among newly diagnosed and untreated hypertensive patients in a Swedish primary care area. Scand J Prim Health Care (2011) 0.81
Is primary hyperaldosteronism a risk factor for aortic dissection? Cardiology (2006) 0.80
Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically. J Clin Endocrinol Metab (2011) 0.79
Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure. Ann Pharmacother (2004) 0.78
Proportion of Patients With Hypertension Resolution Following Adrenalectomy for Primary Aldosteronism: A Systematic Review and Meta-Analysis. J Clin Hypertens (Greenwich) (2016) 0.77
Effect of age on aldosterone/renin ratio (ARR) and comparison of screening accuracy of ARR plus elevated serum aldosterone concentration for primary aldosteronism screening in different age groups. Endocrine (2012) 0.77
Inherited forms of mineralocorticoid hypertension. Best Pract Res Clin Endocrinol Metab (2015) 0.77
β-Blocker withdrawal is preferable for accurate interpretation of the aldosterone-renin ratio in chronically treated hypertension. Clin Endocrinol (Oxf) (2015) 0.77
Effects of Treating Primary Aldosteronism on Renal Function. J Clin Hypertens (Greenwich) (2016) 0.76